Clinical Uses of Antiestrogens
- 1 January 1996
- journal article
- review article
- Published by Wolters Kluwer Health in Obstetrical & Gynecological Survey
- Vol. 51 (1) , 45-59
- https://doi.org/10.1097/00006254-199601000-00021
Abstract
An antiestrogen is a compound that blocks the action of estrogen. Most synthetic antiestrogens have agonistic or antagonistic activity depending on the tissue and the endogenous estrogen mileu. The triphenylethylene derivatives, clomiphene and tamoxifen, are the antiestrogens in greatest clinical use. Their biologic effects, clinical indications, and risks are reviewed. Novel antiestrogens which are beginning to be studied clinically include the benzothiophene derivative, raloxifene and the "pure" antiestrogens such as ICI 182,780. New clinical indications for existing compounds as well as the development of novel antiestrogens may lead to better treatment options for endocrine-dependent conditions.Keywords
This publication has 145 references indexed in Scilit:
- Endometrial Changes with Tamoxifen: Comparison between Tamoxifen-Treated and Nontreated Asymptomatic, Postmenopausal Breast Cancer PatientsGynecologic Oncology, 1994
- Desmoid tumours treated with triphenylethylenesEuropean Journal Of Cancer, 1992
- Oncogenic potential of tamoxifen on endometria of postmenopausal women with breast cancer—Preliminary reportGynecologic Oncology, 1991
- Introduction to toremifeneBreast Cancer Research and Treatment, 1990
- Anti-oestrogenic and anti-tumour properties of prolonged tamoxifen therapy in C3H/OUJ miceEuropean Journal of Cancer and Clinical Oncology, 1990
- A Randomized Clinical Trial Evaluating Tamoxifen in the Treatment of Patients with Node-Negative Breast Cancer Who Have Estrogen-Receptor–Positive TumorsNew England Journal of Medicine, 1989
- Adjuvant tamoxifen in primary breast cancer: Influence on plasma lipids and antithrombin III levelsBreast Cancer Research and Treatment, 1988
- Chemohormonal therapy and endocrine function in breast cancer patientsCancer, 1985
- Effects of a new antiestrogen, keoxifene (LY156758), on growth of carcinogen-induced mammary tumors and on LH and prolactin levelsLife Sciences, 1983
- Antagonism of estrogen action with a new benzothiophene derived antiestrogenLife Sciences, 1983